PharmAla discloses 17.3% stake in Jupiter Neurosciences

PharmAla Biotech Holdings Inc. reports beneficial ownership of 17.3% of Jupiter Neurosciences’ common stock with sole voting and dispositive power.

Rhea-AI Filing Summary

Jupiter Neurosciences, Inc. (JUNS) has a significant shareholder disclosure showing that PharmAla Biotech Holdings Inc. beneficially owns 132,867 shares of Jupiter Neurosciences common stock, par value $0.0001 per share. This represents 17.3% of the class, based on 770,081 outstanding shares.

PharmAla Biotech Holdings Inc., organized in Ontario, Canada, reports sole voting and sole dispositive power over all 132,867 shares and no shared voting or shared dispositive power.

Key Figures

Shares beneficially owned: 132,867 shares Percent of class: 17.3% Shares outstanding baseline: 770,081 shares +2 more

5 metrics

Shares beneficially owned 132,867 shares Common stock of Jupiter Neurosciences, Inc. beneficially owned by PharmAla Biotech Holdings Inc.

Percent of class 17.3% Portion of Jupiter Neurosciences common stock class held by PharmAla Biotech Holdings Inc.

Shares outstanding baseline 770,081 shares Outstanding Jupiter Neurosciences shares used to calculate PharmAla’s ownership percentage

Sole voting power 132,867 shares Shares over which PharmAla Biotech Holdings Inc. has sole power to vote or direct the vote

Sole dispositive power 132,867 shares Shares over which PharmAla Biotech Holdings Inc. has sole power to dispose or direct the disposition

Key Terms

beneficially owned, Percent of class, sole voting power, sole dispositive power, +1 more

5 terms

beneficially owned financial

"Ownership (a) | Amount beneficially owned: 132,867"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

Percent of class financial

"(b) | Percent of class: 17.3 %"

Percent of class is the portion of a specific category of securities—such as a company’s common shares, preferred shares, or a bond series—that takes part in or approves a corporate action (vote, consent, tender, etc.). Investors watch this number because it reveals how much support or opposition exists within that particular shareholder group; like counting how many members of a club back a proposal, it can determine whether a plan passes or how influence is distributed.

sole voting power financial

"Sole Voting Power 132,867.00"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

sole dispositive power financial

"Sole Dispositive Power 132,867.00"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

Schedule 13G regulatory

"Form Type: SCHEDULE 13G"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What percentage of Jupiter Neurosciences (JUNS) does PharmAla Biotech Holdings Inc. own?

PharmAla Biotech Holdings Inc. beneficially owns 17.3% of Jupiter Neurosciences’ common stock, based on 770,081 outstanding shares reported in the filing.

How many JUNS shares does PharmAla Biotech Holdings Inc. beneficially own?

PharmAla Biotech Holdings Inc. beneficially owns 132,867 shares of Jupiter Neurosciences, Inc. common stock, with sole voting and sole dispositive power over all of these shares.

Does PharmAla Biotech Holdings Inc. have sole or shared voting power over JUNS shares?

PharmAla Biotech Holdings Inc. reports sole voting power over 132,867 shares of Jupiter Neurosciences and no shared voting power over any shares.

What dispositive power does PharmAla Biotech Holdings Inc. report over JUNS stock?

PharmAla Biotech Holdings Inc. reports sole dispositive power over 132,867 shares of Jupiter Neurosciences common stock and no shared dispositive power over any shares.

What share count did the JUNS Schedule 13G use to calculate PharmAla’s ownership percentage?

The reported 17.3% ownership by PharmAla Biotech Holdings Inc. is based on 770,081 outstanding shares of Jupiter Neurosciences, Inc. as referenced in the filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/22/2026 - 11:59 AM Accepted by SEC EDGAR 09/22/2026 - 11:59 AM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Jupiter Neurosciences, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

48208B203

(CUSIP Number)

08/20/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 48208B203

1

Names of Reporting Persons

PharmAla Biotech Holdings Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

ONTARIO, CANADA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 132,867.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 132,867.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

132,867.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

17.3 %

12

Type of Reporting Person (See Instructions)

CO

Comment for Type of Reporting Person: Based on 770,081 outstanding Issuer shares

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Jupiter Neurosciences, Inc.
(b)	Address of issuer's principal executive offices: 11621 Kew Gardens Avenue, Suite 210, Palm Beach Gardens FL 33410
Item 2.
(a)	Name of person filing: PharmAla Biotech Holdings Inc.
(b)	Address or principal business office or, if none, residence: 1 Adelaide Street E., Suite 801 Toronto, Ontario M5C 2VP Canada
(c)	Citizenship: Ontario, Canada
(d)	Title of class of securities: Common Stock, par value $0.0001 per share
(e)	CUSIP Number(s): 48208B203
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 132,867
(b)	Percent of class: 17.3 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 132,867
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 132,867
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

PharmAla Biotech Holdings Inc.

Signature:	/s/ William Avery
Name/Title:	Chief Financial Officer
Date:	09/22/2026